Related Experiment Video
Updated: May 13, 2026
12:01
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.7K
The α-Synuclein Seeding Amplification Assay for Parkinson's Disease
Ling-Xiao Yi1, Eng King Tan1,2,3, Zhi Dong Zhou1,3
1National Neuroscience Institute of Singapore, 11 Jalan Tan Tock Seng, Singapore 30843, Singapore.
International Journal of Molecular Sciences
|January 11, 2025
Summary
Parkinson's disease diagnosis is enhanced by a new blood test detecting abnormal alpha-synuclein (α-Syn) protein seeding. This assay shows promise for monitoring disease progression and guiding anti-Parkinson's therapy.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Parkinson's disease (PD) is a prevalent neurodegenerative disorder with no cure, primarily diagnosed through clinical symptoms.
- Pathologically, PD is characterized by the aggregation of misfolded alpha-synuclein (α-Syn) proteins into Lewy bodies.
- Misfolded α-Syn acts as a prion-like seed, promoting further aggregation and disease progression.
Purpose of the Study:
- To evaluate the utility of a blood-based α-Syn seeding amplification assay (SAA) for Parkinson's disease detection.
- To identify pathological α-Syn seeding activity in diverse PD patient cohorts.
- To explore the potential of SAA in improving PD diagnosis, monitoring, and therapeutic strategies.
Main Methods:
- Utilized a blood-based α-Syn seeding amplification assay (SAA) to detect pathological α-Syn seeding activity.
- Analyzed PD patients with various genetic variants, including Parkin (PRKN), Leucine-rich repeat kinase 2 (LRRK2), and glucocerebrosidase (GBA).
- Included sporadic PD cases in the analysis.
Main Results:
- Identified pathological α-Syn seeding activity in PD patients with PRKN gene variants using the SAA.
- Detected similar pathological α-Syn seeding activity in sporadic PD and PD patients with LRRK2 or GBA variants.
- Demonstrated the capability of α-Syn SAA to detect seeding activity across different PD subtypes.
Conclusions:
- The α-Syn SAA is a promising tool for detecting pathological α-Syn seeding activity in the blood of Parkinson's disease patients.
- This assay has significant potential to enhance PD diagnosis, monitor disease progression, predict prognosis, and aid in the development of anti-PD therapies.
- Further research and validation are needed to address the challenges and limitations of the α-Syn SAA protocol for widespread clinical application.
